TruScreen Fact Sheet

Cervical Cancer Elimination
2
TruScreen Key Investment Highlights
TruScreen Group Limited (NZX/ASX:TRU) provides a world class, real time cervical cancer screening medical device.
TruScreen ® Ultra is portable, affordable, easy to use, painless and can be operated by non-doctor. TruScreen
technology is recommended by the Chinese Obstetrics and Gynecological Association ‘s Blue Book and features in the
Chinese Society of Colposcopy and Cervical Pathology National Screening Guidelines. TruScreen ® Ultra device is
registered in 20 countries and commercially used in China, Vietnam, Mexico, Zimbabwe, Russia and Poland, and Saudi
Arabia.
Capital Raise Offer Details
TruScreen is seeking growth capital to raise up to NZD $2.8 million through the issue of 140,008,446 New
Shares at NZ$0.02/A$0.0187 per share. A 31% discount of the share price at market close 9 February 2024/
Funds will be used for working capital (inventory, receivables and marketing) to capitalise on China growth
and new market opportunities in China, Vietnam, Saudi Arabia and Mexico.
Investor Fact Sheet
February 2024
Management of
90% of invasive
cancer cases
contributing to WHO’s 70% screening target
Women in LMICS are most at risk
►1BN+ women of screening age in LMICs
►85% of cases & 87% of deaths occur in
LMICs
Fourth most common cancer in women worldwide
►570,000 new cases each year
►311,000 deaths
►Most diagnoses occur at age 35-44
90% coverage of HPV
Vaccination of girls
(by 15 years of age)
70% coverage of screening
and 90% treatment of
precancerous lesions
The World Health
Organisation
has set a target to
eliminate cervical cancer
by the end of the century
1
Business Market Insights, June 2023
2
Cervical cancer (who.int)
Largest market and opportunity– China
►China NZ$1.78 M sales 9 months YTD December 2023,
77% up on prior year
►Rapid China growth supported by Made in China (MIC)
status secured in FY 2022 –preferred market access
►MIC creates strong barrier to entry for potential, future
competitors
►TruScreen recommended by COGA BLUE BOOK, a
Consensus, by the top country gynaecologists
►CSCCP Specialist Guideline features TruScreen
technology
Group - 9 mths to December 2023 sales growth units:
devices 40% growth and SUS 22% growth comparing with
same period FY 2023
Prior year - FY 2023 snapshot, (COVID impacted)
►FY23 Sales NZ$1.6m, device installations up 15%
YOY, despite Covid lockdown in China
►Total Revenue NZ$2.2m
Recent success in Mexico with approval to enter public
health sector, and Saudi Arabia with reimbursement
approval from health insurers supports new growth.
High growth opportunity

Dr. Beata Edling, Chief Executive Officer
Guy Robertson, Chief Financial Officer
Edmond Capcelea, Chief Technology Officer
Dr. Jerry Tan, Lead Commercial Manager, APAC,
Americas
As of 9 February 2024
Market Cap: NZ $12 million
Share Price: NZ$0.028
Cash Position: NZ$0.3 million
This fact sheet should be viewed in conjunction with TruScreen’s latest Financial information and any accompanying NZX/ASX releases. The
information presented is a snapshot and does not contain supporting information necessary to make an investment decision. It is not
intended to act as a recommendation to acquire TruScreen shares. There can be no assurance that actual outcomes will not materially differ
from the forward looking statements presented. A number of important factors could cause actual results or performance to differ materially
from the forward-looking statements. The forward-looking statements are based on information available to TruScreen as at the date of this
fact sheet. Except as required by law (including the NZX Listing Rules), TruScreen undertakes no obligation to provide any additional or
updated information whether as a result of new information, future events or results or otherwise. TruScreen, its advisers, affiliates, related
bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the
currency, accuracy, reliability or completeness of information in this fact sheet.
TruScreen Business Model
Executive Team
Key Financial Details
Investor Fact Sheet
February 2024
INVESTOR CONTACT
guyrobertson@truscreen.com
High-growth markets
►APAC Cervical Cancer market to
reach 4B USD by 2028 with
CAGR > 7%
1
►China remains the biggest
opportunity with two new
national screening Guidelines
►Zimbabwe, Saudi Arabia,Mexico,
Vietnam poised for growth
Consumable revenue model
World-class technology
►Single visit, non-invasive, mobile
screening technology, artificial
intelligence enabled
►No laboratory infrastructure
required; nurse administered
►Accuracy equal to, or better,
than leading screening methods
►Recommended by COGA Blue
Book and CSCCP, China
►Annuity revenue stream (Single
Use Sensor). FY24 sales revenue
growth 35%
►Large global distribution
network
►Ramping up growth in China and
existing markets
►Ongoing manufacturing and
logistics improvements to drive
COGS down